Urologic Oncologist and Scientist at Northwestern University K-index:3.7
Chicago
Joined July 2009
- Tweets2.4K
- Following4K
- Followers3.8K
- Likes15K
Joshua Meeks retweeted
We need thoughtful, forward-thinking surgeons like @wandering_gu at the ASCO leadership table, bringing the surgical perspective to how we advance multidisciplinary cancer care.
Todd Morgan is an exceptional surgeon and researcher, and someone I have tremendous respect for.
Voting is now open asco.org/about-asco/asco-ove…
Joshua Meeks retweeted
BCG has been used as an immunotherapy for bladder cancer for over 50 years, yet its immunoregulatory mechanisms and causes of resistance remain unclear.
doi.org/10.1172/JCI200442
Here, Joshua James Meeks @JoshMeeks, Weiguo Cui @Cui_Lab & team @NUFeinbergMed analyzed the tumor microenvironment in patients with bladder cancer, identifying dynamic regulation of myeloid-T cell interactions as a critical for outcomes of BCG.
The figure shows the study design and patient cohort for immune profiling of the bladder cancer tumor microenvironment during BCG therapy.
#BladderCancer #BCGtherapy
Joshua Meeks retweeted
Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer: doi.org/10.1172/JCI200442
Joshua Meeks retweeted
Exciting opportunity! The AUA is seeking a highly-qualified member to fill the position of AUA’s next Editor of The Journal of Urology®.
🚨 Apply by June 29, 2026 for consideration!
Learn more here ➡️ bit.ly/4aQjJfH
#TheVoiceofUrology
Joshua Meeks retweeted
Thanks so much @MarkTysonMD & @JoshMeeks !! Very appreciative of both of your support and help with the GAIN trial A032303 @ALLIANCE_org @SWOG @eaonc @NRGonc @theNCI
I agree - this is a GREAT trial and my patients have been enthusiastic so far. Thank you @eugene_pietzak for your leadership on this trial
Joshua Meeks retweeted
Presented at #ASCO26:
In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: nej.md/3RuNe00
Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW
@ASCO
ALT A survival analysis graph from a study published in the New England Journal of Medicine shows the percentage of patients over time in months since randomization. The graph compares "ADT plus apalutamide" to "ADT plus placebo." Data includes hazard ratios and confidence intervals. The American Society of Clinical Oncology Meeting is mentioned at the top.
Joshua Meeks retweeted
We ran a mock ODAC for sasanlimab and durvalumab in high risk NMIBC. Results showed one of the agents received more support than the other. This felt surprising and is timely in vote of the recent FDA decisions. #ASCO26 👉 open.spotify.com/episode/2jM…
Joshua Meeks retweeted
Come join us for a deep dive into Clinical Trials in Progress - Hall B, The Square, Learning Lab ... at 9 am ET TODAY #AUA26
Heading to #AUA26? Don’t miss the Clinical Trials in Progress (CTiP) session.
@bbmdmsk and I will be moderating a deep dive as presenters share the raw science and trial designs for the next generation of bladder cancer care - including novel ADCs, gene therapy, and intravesical drug-delivery systems.
Your questions and input could help shape these studies before they reach the finish line.
See you at the Learning Lab in The Square!
#Urology #BladderCancer #MedicalInnovation @AmerUrological
Joshua Meeks retweeted
The FDA approves the signatera ctDNA assay for muscle invasive bladder cancer patients post surgery.
This is based on the results of Imvigor011 study (atezo vs placebo in ctDNA positives, surveillance for the ctDNA negatives).
It opens a new chapter for personalised therapy in urothelial cancer. Focusing on early treatment for those patients that need it and sparing those at lower risk potentially harmful treatment makes sense.
‘It is the first companion diagnostic approval in the field of blood-based MRD.’
natera.com/company/news/sign…
Joshua Meeks retweeted
Congratulations to the newly awarded 2026 National Residency Abstract Olympics winners! 🏆
@CleClinicUro @NM_Urology @WCMUrology
#AUA26
Joshua Meeks retweeted
Perioperative durvalumab (12 months) with neoadjuvant EV (3 cycles) shows ‘statistically significant and clinically meaningful’ improved EFS and OS vs cystectomy alone in MIBC (like KN905 (EVP cs cystectomy)). The shorter period of EV is the major difference in trial designs. Details of efficacy and toxicity will be important. The 3rd arm, where tremelimumab was added as a triplet, did not hit OS at this stage. astrazeneca.com/media-centre… @OncoAlert
Joshua Meeks retweeted
We are very proud of our editor, Jeremy Teoh, who has been invited to deliver the prestigious John K. Lattimer Lecture at the AUA Annual Meeting 2026.
The Lattimer Lecture, first established in 1977, recognises new innovations and practices with the potential to revolutionise urology and medicine more broadly. Previous awardees include distinguished leaders in the field such as Vipul Patel, Ralph Clayman, Glenn Preminger, Curtis Nickel, and Ash Tewari.
Jeremy shared that he feels deeply honoured to receive this recognition as an Asian researcher and warmly invites colleagues and friends to attend the lecture at Hall D at 1:00 PM on 15 May 2026. A group photo will take place outside the hall after the lecture at approximately 1:30 PM.
Congratulations, @jteoh_hk, on this outstanding achievement!
@uroweb
@mroupret
@GPloussard
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
@AmericanUrological
Joshua Meeks retweeted
For 15+ years, our work has shown that histone-modifying enzymes do more than just their catalytic jobs. They also have important non-catalytic roles. Dr. Zibo Zhao just published a great review on COMPASS family enhancer monomethylases and discusses how their loss creates new druggable vulnerabilities. nature.com/articles/s41568-0… Her findings are now in the clinic for treatment of cancers bearing MLL3/4-COMPASS mutations Fingers crossed! @NU_BMG_SQE @NUFeinbergMed @theNASciences @theNAMedicine @CellPressNews @ScienceMagazine @Nature @NatureCancer @MolecularCell @zhao_zibo
Joshua Meeks retweeted
We are pleased to announce the appointment of Joseph Liao, MD, as the next Chair of the Department of Urology, effective August 1.
Read the full announcement from Dean Lloyd Minor: urology.stanford.edu/news/04…
@liaojoe1 @StanfordMed @AmerUrological
Joshua Meeks retweeted
TURBT is one of the most impt surgical skills in managing #bladdercancer
2026 course was another big success. Thank you @olympusamerica for your support
Incredible group of residents fellows and attendings there this year. Thx @JoshMeeks and John Sfakianos for helping teach
Joshua Meeks retweeted
We’re getting the band back together in Nashville for Uromigos Live & Unplugged 2026!
More details coming soon. For now, mark your calendar.
#Uromigos #GUOncology #OncologyCommunity
Joshua Meeks retweeted
@tonivilaseca presenting promising early data for intravesical erdafitinib (Erda-iDRS) “TAR 210” in NMIBC presented at #EAU26
➡️ 83% 12-mo RFS as adjuvant therapy in HR NMIBC (n=26)
➡️ 89% CR at 6 months in IR NMIBC ablative cohort
Targeted #FGFR therapy moving earlier into NMIBC disease states. @JoshMeeks @DrFelixGuerrero @IBCG_BladderCA @BladderCancerUS
Joshua Meeks retweeted
WE ARE HERE‼️
OncoAlert 🚨is Proud to be collaborating with @AUC3_Official and is NOW coming LIVE from Miami🌴 #AUC3 2026 in full swing
ARTICLE HERE: 👉 buff.ly/bAgkPQC
JUST OUT on the management of renal cell and urinary tract cancers from the Advanced Urologic Cancer Consensus Conference (AUC3) and the Expert consensus
Bienvenidos a Miami☀️
@DrRanaMcKay
@montypal
@DrRosenbergMSK
@Wanling50578056
@Dr_Aggen
@AlbigesL
@apolo_andrea
@OncoBellmunt
@bergsa83
@bilenma
@BraunMDPhD
@drjefstathiou
@PGrivasMDPhD
@shilpaonc
@arihakimi
@HHammersMD
@DrDanielHeng
@MichelleDunno17
@EJonasch
@koshkin85
@advocatekidneys
@UrogerliMD
@SurenaMatinMD
@maughanonc
@BradMcG04
@JoshMeeks
@motzermd
@AndreaNecchi
@SimaPorten
@tompowles1
@brian_rini
@sonpavde
@ChadTangMD
@MichvdHeijden
@VincentWenxinXu
@TiansterZhang
@Mustafajsalehmd
@mzugman
#kidneyCancer
#BladderCancer
Joshua Meeks retweeted
Signing off 2025 on a positive note w/ a discussion around @US_FDA approval of #Enfortumab + Pembro (EV303) in MIBC w/ @tompowles1 (design, findings, AEs, role of ctDNA)
Full 🗣️:
⭐️ oncbrothers.com/ev-pembro-mi…
⭐️ “Oncology Brothers” podcast
#BladderCancer @OncUpdates @OncoAlert
Joshua Meeks retweeted
Dear Colleagues,
OncoAlert 🚨is Proud to be collaborating with @AUC3_Official and will be coming LIVE from Miami🌴 in January for #AUC3 2025
ARTICLE HERE: 👉 buff.ly/bAgkPQC
JUST OUT on the management of renal cell and urinary tract cancers from the Advanced Urologic Cancer Consensus Conference (AUC3) and the Expert consensus
SEE you IN MIAMI☀️
@DrRanaMcKay
@montypal
@DrRosenbergMSK
@Wanling50578056
@Dr_Aggen
@AlbigesL
@apolo_andrea
@OncoBellmunt
@bergsa83
@bilenma
@BraunMDPhD
@drjefstathiou
@PGrivasMDPhD
@shilpaonc
@arihakimi
@HHammersMD
@DrDanielHeng
@MichelleDunno17
@EJonasch
@koshkin85
@advocatekidneys
@UrogerliMD
@SurenaMatinMD
@maughanonc
@BradMcG04
@JoshMeeks
@motzermd
@AndreaNecchi
@SimaPorten
@tompowles1
@brian_rini
@sonpavde
@ChadTangMD
@MichvdHeijden
@VincentWenxinXu
@TiansterZhang
#kidneyCancer
#BladderCancer